Combination Radiation Therapy and Chemotherapy: A Logical Basis for Their Clinical Use

Rubin, Philip; Carter, Stephen K.

doi:10.3322/canjclin.26.5.274

Cited by 27 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the LL surgical-adjuvant, metastatic-lung-tumor model presents a dual challenge to potentially useful chemotherapeutic agents. In this regard, six drugs (cytoxan, CCNU, BCNU, MeCCNU, bleomycin, and vincristine) that have been classified as active against human lung disease (Rubin and Carter, 1976), were found to be active against the LL disease model.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of clinically active antineoplastic drugs in a surgical‐adjuvant chemotherapy treatment regimen using the lewis lung (LL) carcinoma

Merker

Wodinsky

Cantor

et al. 1978

Intl Journal of Cancer

View full text Add to dashboard Cite

Surgical‐adjuvant chemotherapy studies were done with BDF1 mice bearing Lewis Lung (LL) carcinoma implanted intramuscularly (IM). Ten days (D10) after implantation, the tumor‐bearing leg was surgically amputated, and intraperitoneal (IP) drug treatment was started either 3 or 5 days after surgery using single‐dose therapy or intermittent treatment given every 4 days for three doses or daily treatment for five doses. The percentage increase in life span (%ILS) was used as the primary measure for evaluation. Data for 17 clinically active drugs showed that surgical‐adjuvant, single‐agent chemotherapy was markedly effective (%ILS>100) in prolonging the life span of tumor‐bearing animals given BCNU, MeCCNU, and cytoxan; moderate activity (%ILS, 40–100) was obtained with bleomycin and vincristine, and marginal activity (%ILS, 35–40) was observed with 5‐fluorouracil (5‐FU), hexamethylmelamine (HMM), procarbazine, and dibromodulcitol. Surgical‐adjuvant, two‐drug‐combination chemotherapy treatment with bleomycin plus MeCCNU or cis‐platinum [cis‐PT(II)] plus CCNU were more effective than single‐drug chemotherapy in prolonging the life span of tumor‐bearing animals. When used in a surgical‐adjuvant chemotherapy‐treatment schedule, the solid tumor model was found to be sensitive to certain antineoplastic drugs that are of clinical benefit in the treatment of human lung cancer. Thus, the model is potentially useful in the search for newer single agents and combinations of drugs against cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of clinically active antineoplastic drugs in a surgical‐adjuvant chemotherapy treatment regimen using the lewis lung (LL) carcinoma

Merker

Wodinsky

Cantor

et al. 1978

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…The next approach was to test the GNP constructs in combined use of radiation therapy and chemotherapy. The integration of chemotherapy with radiation therapy has greatly improved the outcome in cancer treatment (Herscher et al 1999;Rubin and Carter 1976). The standard treatment protocol is to inject chemotherapeutic drugs to the patients prior to the radiation treatment (Rubin and Carter 1976).…”

Section: Gnp-mediated Combined Therapymentioning

confidence: 99%

Gold nanoparticle mediated combined cancer therapy

et al. 2018

View full text Add to dashboard Cite

Background: The combined use of radiation therapy and chemotherapy is commonly being used in cancer treatment. The side effects of the treatment can be further minimized through targeted delivery of anticancer drugs and local enhancement of the radiation dose. Gold nanoparticles (GNPs) can play a significant role in this regard since GNPs can be used as radiation dose enhancers and anticancer drug carriers. Anticancer drug, bleomycin, was chosen as the model drug, since it could be easily conjugated onto GNPs through the gold-thiol bond. Methods: Gold nanoparticles of size 10 nm were synthesized using the citrate reduction method. The surface of The GNPs was modified with a peptide sequence (CKKKK-KKGGRGDMFG) containing the RGD domain and anticancer drug, bleomycin. Human breast cancer cells (MDA-MB-231) were incubated with 0.3 nM concentration of GNPdrug complex for 16 h prior to irradiation with a 2 Gy single fraction of 6 MV X-rays. After the treatment, cells were trypsinized and seeded in 60 mm dishes for clonogenic assay. Damage to DNA was probed using immunofluorescence assay. Results: Cancer cells internalized with the GNP-drug complex had a 32 ± 9% decrease in cell survival and statistically significant enhancement in DNA (deoxyribonucleic acid) damage as compared to control cells (irradiated with no GNPs) after receiving a radiation dose of 2 Gy with 6 MV photons. Conclusions: The experimental results demonstrate that GNP-mediated chemoradiation has the potential to improve cancer care in the near future through enhancement of the local radiation dose and controlled delivery of anticancer drugs.

show abstract

“…Rubin and Carter (1976) published Dr Suit's estimates on the percentage of local failures as a major contributing cause of death for a variety of primary tumour sites. Utilizing the same percentages and applying them to the 1985 estimated annual deaths from primary tumours (Silverberg 1985), an estimate of the number of patients that can potentially benefit by additional improvements in local control provided by adjunctive hyperthermia has been made (table 1).…”

Section: Importance Of Local Controlmentioning

confidence: 99%

Site and disease selection for hyperthermia clinical trials

Kapp

1986

International Journal of Hyperthermia

View full text Add to dashboard Cite

Significant progress has been made in the past 20 years in understanding the biological basis of hyperthermia-induced cytotoxicity, thermoenhancement of radiation therapy and chemotherapy, and in the development of clinically applicable microwave, radiofrequency, ultrasound and thermometry equipment. Numerous uncontrolled trials have suggested strongly that hyperthermia in conjunction with radiation therapy or chemotherapy may contribute to improved local control rates for recurrent or metastatic cancer without excessive morbidity. Carefully designed and well-controlled site and disease-specific prospective randomized trials with standardized hyperthermia and radiation therapy techniques, adequate thermometry, precise end points for tumour control and normal tissue toxicity are now essential to establish the role of hyperthermia in cancer management. Criteria for tumour site selection will be explored for trials employing radiation therapy and local-regional hyperthermia. Examples of sites selected will be presented which represent areas that can, with current technology, usually be adequately heated, and in which significant patient benefit may result from improved local-regional control.

show abstract

Combination Radiation Therapy and Chemotherapy: A Logical Basis for Their Clinical Use

Cited by 27 publications

References 30 publications

Effectiveness of clinically active antineoplastic drugs in a surgical‐adjuvant chemotherapy treatment regimen using the lewis lung (LL) carcinoma

Effectiveness of clinically active antineoplastic drugs in a surgical‐adjuvant chemotherapy treatment regimen using the lewis lung (LL) carcinoma

Gold nanoparticle mediated combined cancer therapy

Site and disease selection for hyperthermia clinical trials

Contact Info

Product

Resources

About